There were 1,819 press releases posted in the last 24 hours and 358,634 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Calithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image